Only doubling or tripling a-synuclein expression significantly increases the risk of developing Parkinson's disease. In this issue of Neuron, Nemani et al. show that this modest overexpression of a-synuclein does not lead to obvious toxicity in the near term, but impairs glutamate and dopamine release, potentially leading to broad network dysfunction and eventual pathology.
Parkinson's disease (PD) is a widespread, aging-related neurodegenerative disease. One of the hallmarks of PD is the formation of intracellular proteinaceous inclusions referred to as Lewy bodies (LBs) (Braak et al., 2003) . One of the principal components of LBs is a-synuclein (asyn). Elevating asyn expression by duplication or triplication of the asyn gene (SNCA) produces inclusions and increases the risk of developing PD (Waxman and Giasson, 2009 ). The asyn protein also has been implicated in a variety of other neurodegenerative diseases, like Alzheimer's disease and multiple system atrophy, making it one of the most studied molecules in the last decade.
Yet, in spite of all this effort, how modest overexpression or mutation of asyn might lead to neuronal pathology is still not agreed upon. a-Synuclein is a small (140 amino acid), highly charged protein that is preferentially localized in presynaptic terminals (George et al., 1995) where it has been suggested to shape synaptic transmission (Abeliovich et al., 2000; Cabin et al., 2002; Chandra et al., 2005; Fortin et al., 2005) . But, the putative synaptic role of asyn is based largely upon the consequences of knocking it out (where the effects are modest at best) or upon dramatically overexpressing it (where there might be a toxic gain of function). In fact, the effect of overexpressing asyn on synaptic transmitter release has not been directly examined. To be sure, the various overexpression models have told us a great deal about the mechanisms underlying synucleinopathies; however, what they tell us about PD, where modest overexpression of asyn can significantly elevate the risk of becoming symptomatic, is unclear.
The studies described in the article by Nemani et al. in this issue of Neuron (Nemani et al., 2010) bring us considerably closer to an understanding of how this might happen. Using an elegant combination of anatomical, optical, and physiological approaches with both in vitro and in vivo model systems, the authors show that increasing the expression of asyn by 2-to 3-fold inhibits neurotransmitter release in glutamatergic hippocampal pyramidal neurons and mesencephalic dopaminergic neurons. At these expression levels, asyn has no obvious toxicity and does not form intracellular inclusions that foreshadow the formation of LBs. The inhibition does not appear to be a consequence of a reduction in the number of transmitter-containing vesicles (as judged from ultrastructural analysis) or of a deficit in vesicular fusion or endocytosis but rather of the failure to get recycling vesicles clustered near synaptic release sites. This clustering deficit reduces the number of vesicles that fuse with the membrane during an action potential and, since quantal size is unchanged, to a reduction in the amount of transmitter released, particularly if the terminal is pushed by repetitive stimulation. Because asyn is widely expressed and the consequences of its overexpression are not limited to a particular cell type, Nemani et al.'s results suggest that duplication or triplication of SNCA should have a negative impact on the functioning of most, if not all, brain circuits.
Precisely how elevating asyn expression impairs clustering of vesicles near the synapse remains to be worked out. Not all the mutations of asyn associated with familial forms of PD affected release in the same way: asyn with the A30P mutation lost its ability to inhibit transmitter release, whereas asyn with the A53T and E46K mutations retained this capacity, suggesting that amino terminal membrane binding was a key step in the inhibition. Synapsins and complexinsproteins involved in vesicle mobilization and fusion-were downregulated by boosting the abundance of asyn. But the authors argue that this alteration is not enough to explain the observed synaptic phenomenology, pointing to another function of asyn. A potential clue about this ''other'' role comes from the fact that the effect on release is dose dependent, scaling with the level of asyn expression. This isn't what would be expected if asyn were taking on a completely new role in synaptic function as expression rose. This dose dependence, along with the ability of b-and g-synuclein to substitute for asyn in regulating transmitter release, suggests that asyn might normally be more important in synaptic function than one would infer from the consequences of knocking it out.
What does this study tell us about pathogenesis in PD (or other synucleinopathies)? One of the most widely discussed features of the LB pathology in PD is its distribution (Braak et al., 2003) . Although it is far from clear how LB formation is linked to the severity of PD symptoms (Jellinger, 2009) , there is no doubt that LBs are found distributed along the neuroaxis in early stages of the disease and they are not limited to dopaminergic neurons in the mesencephalon. The generic deficit in transmitter release described Nemani et al. is consistent with the proposition that PD is a much broader disorder than that inferred from the dopaminedependent motor symptoms. But how a deficit in transmitter release might lead to LB pathology or neurodegeneration is unresolved at this point. It could be that neurons attempt to compensate for the inhibition by increasing spiking or by elevating other aspects of synaptic transmission (although neither was seen in the time frame of the experiments conducted here). A compensation of this sort could impair global brain function and modestly elevate the proteostatic burden on neurons, resulting in a slow accumulation of cellular deficits that results in relatively widespread LB formation only late in life.
Although the deficit predicted by Nemani et al. should be widespread, it is possible that its impact is felt more by some neurons than others. Some of the most vulnerable neurons in PD-dopaminergic neurons in the substantia nigras pars compacta, noradrenergic neurons in the locus ceruleus, serotonergic neurons in the raphe nuclei, and cholinergic neurons in the basal forebrain nuclei (Jellinger, 1991) -have enormous axonal fields with orders of magnitude more synaptic terminals than most neurons (e.g., Matsuda et al., 2009) . Moreover, all of these neurons are spontaneously active in vivo, continually releasing transmitter in target structures like the striatum, cerebral cortex, and hippocampus (Baraban and Aghajanian, 1980; Chan et al., 2007; Vinogradova et al., 1980; Williams et al., 1984) . This sustained transmitter release is important to their targets, and all of these neurons have feedback systems at their terminals (e.g., autoreceptors that regulate the entry of calcium triggering exocytosis) to make sure that they are doing their job. It is not difficult to imagine that compromising the ability of these neurons to release transmitter might force them to work even harder than demanded by their normal role in brain, and that, after fifty or sixty years, they are left with axonal pathology (Galvin et al., 1999) and LBs.
